GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (FRA:0T2) » Definitions » EV-to-FCF

Traws Pharma (FRA:0T2) EV-to-FCF : 0.29 (As of Apr. 29, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Traws Pharma's Enterprise Value is €-4.77 Mil. Traws Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-16.64 Mil. Therefore, Traws Pharma's EV-to-FCF for today is 0.29.

The historical rank and industry rank for Traws Pharma's EV-to-FCF or its related term are showing as below:

FRA:0T2' s EV-to-FCF Range Over the Past 10 Years
Min: -32.49   Med: -0.18   Max: 1.75
Current: 0.29

During the past 13 years, the highest EV-to-FCF of Traws Pharma was 1.75. The lowest was -32.49. And the median was -0.18.

FRA:0T2's EV-to-FCF is ranked better than
84.36% of 390 companies
in the Biotechnology industry
Industry Median: 4.475 vs FRA:0T2: 0.29

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-29), Traws Pharma's stock price is €0.585. Traws Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.846. Therefore, Traws Pharma's PE Ratio for today is At Loss.


Traws Pharma EV-to-FCF Historical Data

The historical data trend for Traws Pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma EV-to-FCF Chart

Traws Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.95 -2.93 0.09 1.55 0.29

Traws Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.55 1.14 0.30 0.59 0.29

Competitive Comparison of Traws Pharma's EV-to-FCF

For the Biotechnology subindustry, Traws Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Traws Pharma's EV-to-FCF falls into.



Traws Pharma EV-to-FCF Calculation

Traws Pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-4.770/-16.636
=0.29

Traws Pharma's current Enterprise Value is €-4.77 Mil.
Traws Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-16.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Traws Pharma  (FRA:0T2) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Traws Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.585/-0.846
=At Loss

Traws Pharma's share price for today is €0.585.
Traws Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.846.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Traws Pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Traws Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Traws Pharma (FRA:0T2) Business Description

Traded in Other Exchanges
Address
12 Penns Trail, Newtown, PA, USA, 18940
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Traws Pharma (FRA:0T2) Headlines

No Headlines